<DOC>
	<DOCNO>NCT00064610</DOCNO>
	<brief_summary>The purpose study evaluate safe PS-341 ( VELCADE ) give Docetaxel ( Taxotere ) patient androgen-independent prostate cancer , also see effect ( good bad ) cancer .</brief_summary>
	<brief_title>Phase I/II Dose Escalation Study VELCADEÂ® Docetaxel Patients With Advanced Androgen-Independent Prostate Cancer</brief_title>
	<detailed_description>This dose escalation study , mean first group patient receive low dose PS-341 ( VELCADE ) Docetaxel ( Taxotere ) . If low dose VELCADE Taxotere appear safe , next group patient receive high dose VELCADE Taxotere .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Inclusion criterion Each patient must meet follow inclusion criterion enrol study : Patient histologicallyconfirmed advanced and/or metastatic androgenindependent prostate cancer require antineoplastic treatment . Previous concurrent hormone therapy luteinizing hormonereleasing hormone analog ( e.g. , leuprolide ) preclude enrollment study . Patient progressive measurable evaluable disease , define meeting least one follow three criterion [ 1 ] : 1 . Progressive measurable disease ( change size lymph node parenchymal mass physical examination xray ) . 2 . Progressive bone metastasis [ presence new lesion ( ) bone scan ] . 3 . Progressive PSA , evidence two separate measurement take least one week apart confirm third , necessary , fourth measurement . If third measurement great second measurement , fourth measurement must take ; fourth measurement must great second measurement patient eligible enrollment study . The confirmatory PSA measurement ( i.e. , third , applicable , fourth PSA measurement ) must great equal 5 ng/mL . Patient 18 year age old . Patient Karnofsky performance status 60 % great . Patient life expectancy three month longer . Patient follow pretreatment laboratory data within 14 day first study drug dose : Absolute neutrophil count ( ANC ) great equal 1,500/mm3 . Platelets great equal to100,000/mm3 . Hemoglobin &gt; 8.0 g/dL . Serum creatinine less equal 2.5 mg/dL . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care . Patient agree use acceptable barrier method contraception Screening 90 day last study drug dose . [ It recommend female partner male patient enrol study also use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) . ] Exclusion criterion Patients meet follow exclusion criterion enrol study . Patient receive chemotherapy within four week , nitrosoureas within six week , antibody therapy within eight week enrollment . Patient receive radiation therapy within four week enrollment . Patient recover toxic effect previous chemotherapy radiation antibody therapy . Patient receive treatment flutamide within four week enrollment nilutamide bicalutamide within six week enrollment . Patient major surgery within four week enrollment . Patient history allergic reaction diuretic antiemetic suggest administered conjunction study drug Patient history severe hypersensitivity reaction docetaxel agent formulate polysorbate 80 . Patient myocardial infarction within six month enrollment uncontrolled angina , severe uncontrolled ventricular arrhythmia , symptomatic congestive heart failure , unstable angina pectoris , electrocardiographic evidence acute ischemia Patient uncontrolled brain metastasis central nervous system disease . Patient Grade 2 high peripheral neuropathy Patient follow pretreatment laboratory data within 14 day first study drug dose : Total bilirubin &gt; upper limit normal ( ULN ) . Alanine transaminase ( ALT ) and/or aspartate transaminase ( AST ) &gt; 1.5 x ULN concurrent alkaline phosphatase &gt; 2.5 x ULN . Alkaline phosphatase &gt; 5 x ULN , unless show fractionation bonederived AST , ALT , bilirubin , gamma glutamyl transferase ( GGT ) , 5'nucleotidase &lt; 1.5 x ULN bilirubin within normal range . Serum testosterone 50 ng/mL high . Patient HIVinfected . Patient hepatitis B surface antigen positive previously document hepatitis C infection . Patient uncontrolled intercurrent illness ( e.g. , active infection ) . Patient another serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Advanced androgen-independent prostate cancer</keyword>
</DOC>